What question did this study set out to answer?

Assess the effectiveness of androgen therapy in patients with agnogenic myeloid metaplasia and the predictive value of chromosomal studies.

January 15, 1982Cancer

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival

View Full Paper

Ask AI

Bookmark

Authors

EBEmmanuel C. BesaFred Hutch Cancer Center PNPeter C. Nowell̀University of Minnesota NGNancy L. GellerGeneral Cardiology

Discussion

Member takes

Implication

Randomized trial analyzes androgen therapy outcomes in patients with agnogenic myeloid metaplasia, suggesting chromosomal studies can predict survival.

Key Points

Assess the effectiveness of androgen therapy in patients with agnogenic myeloid metaplasia and the predictive value of chromosomal studies.
Analyzed responses of 23 patients to androgen therapy, measuring hematocrit changes over three months.
Conducted chromosome studies to evaluate cytogenetic alterations and their correlation with therapy response.
Evaluated various clinical parameters including thrombocytopenia and bone marrow activity.
57% of patients responded with increased hematocrit, eliminating transfusion needs.
92% of patients with normal chromosomes responded favorably compared to only 22% with chromosomal abnormalities.
Mean survival time for responders was 5.5 years versus 2 years for nonresponders.

Cite This Study

Besa et al. (1982) studied this question.

synapsesocial.com/papers/6a0ec74137aeb0126447ab4c https://doi.org/10.1002/1097-0142(19820115)49:2<308::aid-cncr2820490217>3.0.co;2-4

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial analyzes androgen therapy outcomes in patients with agnogenic myeloid metaplasia, suggesting chromosomal studies can predict survival.